Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2018 Jan 18

PMID 29339390

Citations 17

Authors

Dora Posfai

Amber L Eubanks

Allison I Keim

Kuan-Yi Lu

Grace Z Wang

Philip F Hughes

Nobutaka Kato

Timothy A Haystead

Emily R Derbyshire

Affiliations

Soon will be listed here.

Abstract

Malaria remains a global health burden partly due to parasite resistance to first-line therapeutics. The molecular chaperone heat shock protein 90 (Hsp90) has emerged as an essential protein for blood-stage parasites, but details about its function during malaria's elusive liver stage are unclear. We used target-based screens to identify compounds that bind to and human Hsp90, which revealed insights into chemotypes with species-selective binding. Using cell-based malaria assays, we demonstrate that all identified Hsp90-binding compounds are liver- and blood-stage inhibitors. Additionally, the Hsp90 inhibitor SNX-0723 in combination with the phosphatidylinositol 3-kinase inhibitor PIK-75 synergistically reduces the liver-stage parasite load. Time course inhibition studies with the Hsp90 inhibitors and expression analysis support a role for Hsp90 in late-liver-stage parasite development. Our results suggest that Hsp90 is essential to liver- and blood-stage parasite infections and highlight an attractive route for development of species-selective Hsp90 inhibitors that may act synergistically in combination therapies to prevent and treat malaria.

Citing Articles

Auto QSAR-based active learning docking for hit identification of potential inhibitors of Plasmodium falciparum Hsp90 as antimalarial agents.

Matlhodi T, Makatsela L, Dongola T, Simelane M, Shonhai A, Gumede N PLoS One. 2024; 19(11):e0308969.

PMID: 39585817 PMC: 11588265. DOI: 10.1371/journal.pone.0308969.

Screening the Global Health Priority Box against Plasmodium berghei liver stage parasites using an inexpensive luciferase detection protocol.

Nguyen G, Cooper C, McWhorter O, Sharma R, Elliot A, Ruberto A Malar J. 2024; 23(1):357.

PMID: 39580415 PMC: 11585928. DOI: 10.1186/s12936-024-05155-y.

Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome.

Mansfield C, Quan B, Chirgwin M, Eduful B, Hughes P, Neveu G Cell Chem Biol. 2024; 31(4):729-742.e13.

PMID: 38492573 PMC: 11031320. DOI: 10.1016/j.chembiol.2024.02.008.

Ursolic acid acetate and iso-mukaadial acetate bind to Plasmodium falciparum Hsp90, abrogating its chaperone function in vitro.

Nndwammbi A, Dongola T, Shonhai A, Mokoena F, Pooe O, Simelane M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):5179-5192.

PMID: 38252299 PMC: 11166764. DOI: 10.1007/s00210-024-02944-9.

Pharmacophore Model-Based Virtual Screening Workflow for Discovery of Inhibitors Targeting Hsp90.

Mafethe O, Ntseane T, Dongola T, Shonhai A, Gumede N, Mokoena F ACS Omega. 2023; 8(41):38220-38232.

PMID: 37867657 PMC: 10586269. DOI: 10.1021/acsomega.3c04494.

References

Itoe M, Sampaio J, Cabal G, Real E, Zuzarte-Luis V, March S . Host cell phosphatidylcholine is a key mediator of malaria parasite survival during liver stage infection. Cell Host Microbe. 2014; 16(6):778-86. PMC: 4271766. DOI: 10.1016/j.chom.2014.11.006. View

Cowen L, Singh S, Kohler J, Collins C, Zaas A, Schell W . Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009; 106(8):2818-23. PMC: 2650349. DOI: 10.1073/pnas.0813394106. View

Hall N, Karras M, Raine J, Carlton J, Kooij T, Berriman M . A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science. 2005; 307(5706):82-6. DOI: 10.1126/science.1103717. View

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

Krohn K, Link J . Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nucl Med Biol. 2003; 30(8):819-26. DOI: 10.1016/s0969-8051(03)00132-x. View

Banumathy G, Singh V, Pavithra S, Tatu U . Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem. 2003; 278(20):18336-45. DOI: 10.1074/jbc.M211309200. View

Ejigiri I, Sinnis P . Plasmodium sporozoite-host interactions from the dermis to the hepatocyte. Curr Opin Microbiol. 2009; 12(4):401-7. PMC: 2725221. DOI: 10.1016/j.mib.2009.06.006. View

Grenert J, SULLIVAN W, Fadden P, Haystead T, Clark J, Mimnaugh E . The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997; 272(38):23843-50. DOI: 10.1074/jbc.272.38.23843. View

Sawarkar R, Sievers C, Paro R . Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell. 2012; 149(4):807-18. DOI: 10.1016/j.cell.2012.02.061. View

10.

Meister S, Plouffe D, Kuhen K, Bonamy G, Wu T, Barnes S . Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011; 334(6061):1372-7. PMC: 3473092. DOI: 10.1126/science.1211936. View

11.

Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F . 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005; 11(10):1088-95. DOI: 10.1038/nm1298. View

12.

Neckers L, Mimnaugh E, Schulte T . Hsp90 as an anti-cancer target. Drug Resist Updat. 2001; 2(3):165-172. DOI: 10.1054/drup.1999.0082. View

13.

Pallavi R, Roy N, Nageshan R, Talukdar P, Pavithra S, Reddy R . Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem. 2010; 285(49):37964-75. PMC: 2992230. DOI: 10.1074/jbc.M110.155317. View

14.

Kumar R, Musiyenko A, Barik S . The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J. 2003; 2:30. PMC: 201030. DOI: 10.1186/1475-2875-2-30. View

15.

Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N . Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen. 2004; 9(5):375-81. DOI: 10.1177/1087057104265995. View

16.

Nguyen M, Kniess R, Daturpalli S, Le Breton L, Ke X, Chen X . Isoform-Specific Phosphorylation in Human Hsp90β Affects Interaction with Clients and the Cochaperone Cdc37. J Mol Biol. 2017; 429(5):732-752. DOI: 10.1016/j.jmb.2017.01.011. View

17.

Huang K, Veal J, Fadden R, Rice J, Eaves J, Strachan J . Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009; 52(14):4288-305. DOI: 10.1021/jm900230j. View

18.

Mutabingwa T . Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!. Acta Trop. 2005; 95(3):305-15. DOI: 10.1016/j.actatropica.2005.06.009. View

19.

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

20.

Devaney E, ONeill K, Harnett W, Whitesell L, Kinnaird J . Hsp90 is essential in the filarial nematode Brugia pahangi. Int J Parasitol. 2005; 35(6):627-36. DOI: 10.1016/j.ijpara.2005.01.007. View